Cybrexa Therapeutics is a clinical-stage biotechnology company at the forefront of developing a new class of cancer therapeutics. Leveraging its proprietary alphalex™ technology platform, Cybrexa aims to deliver powerful anti-cancer agents directly and preferentially to tumor cells, thereby minimizing systemic toxicity and enhancing treatment efficacy. The company's pipeline focuses on addressing unmet needs in various oncology indications, with lead candidates progressing through clinical development. Their innovative approach seeks to revolutionize how cancer is treated by improving the therapeutic window of potent cytotoxics.
The New Haven headquarters serves as the central node for Cybrexa's research and development, clinical trial management, strategic partnerships, and corporate operations.
Situated within New Haven's Science Park area, the headquarters benefits from proximity to leading academic institutions and a strong biotech ecosystem, fostering collaboration and access to talent.
The work culture at Cybrexa Therapeutics is characterized by a strong scientific focus, innovation, collaboration, and a patient-centric mission to develop impactful cancer therapies. Employees often describe it as dynamic and driven.
Its location in New Haven is significant for access to world-class research facilities, a skilled talent pool from institutions like Yale, and a supportive environment for biotech startups and clinical-stage companies.
As a clinical-stage company, Cybrexa Therapeutics's global presence is primarily established through its clinical trial sites, which may be located across North America, Europe, and other regions, in collaboration with leading cancer research centers and hospitals. They also engage with the global scientific and investment community through conferences and partnerships.
55 Church Street, 8th Floor
New Haven
CT
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cybrexa Therapeutics' leadership includes:
Cybrexa Therapeutics has been backed by several prominent investors over the years, including:
Over the past year, Cybrexa Therapeutics has focused on strengthening its leadership team to guide its clinical development programs and strategic growth. Notably, the company appointed a new Chief Business Officer.
Discover the tools Cybrexa Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cybrexa Therapeutics likely utilizes common corporate email formats. The most probable structure is [firstinitial][last]@cybrexa.com. For official communication, it is always recommended to use the contact forms or general inquiry emails provided on their official website.
flast@cybrexa.com
Format
phellsund@cybrexa.com
Example
80%
Success rate
Cybrexa Therapeutics Press Release • April 8, 2024
Cybrexa Therapeutics announced the presentation of preclinical data on its novel alphalex™-exatecan conjugate, CBX-15, at the AACR Annual Meeting 2024. The data highlighted CBX-15's superior tumor cell penetration and DNA damage response, suggesting its potential as a treatment for various solid tumors....more
Cybrexa Therapeutics Press Release • October 10, 2023
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to CBX-12 for the treatment of patients with metastatic small cell lung cancer (SCLC) who have progressed following two prior lines of therapy. This designation aims to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need....more
Cybrexa Therapeutics Press Release • May 2, 2023
Cybrexa Therapeutics announced the appointment of Sebastian Guth, Ph.D., as Chief Business Officer. Dr. Guth brings over 20 years of experience in the biopharmaceutical industry, with a strong background in business development, commercialization, and corporate strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cybrexa Therapeutics, are just a search away.